Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
2.190
+0.270 (14.06%)
At close: Mar 9, 2026, 4:00 PM EDT
2.090
-0.100 (-4.57%)
After-hours: Mar 9, 2026, 5:59 PM EDT
Biomerica Revenue
Biomerica had revenue of $1.21M in the quarter ending November 30, 2025, a decrease of -26.04%. This brings the company's revenue in the last twelve months to $4.46M, down -20.10% year-over-year. In the fiscal year ending May 31, 2025, Biomerica had annual revenue of $5.31M, down -1.92%.
Revenue (ttm)
$4.46M
Revenue Growth
-20.10%
P/S Ratio
1.33
Revenue / Employee
$82,537
Employees
54
Market Cap
6.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 5.31M | -104.00K | -1.92% |
| May 31, 2024 | 5.42M | 76.00K | 1.42% |
| May 31, 2023 | 5.34M | -13.53M | -71.71% |
| May 31, 2022 | 18.87M | 11.67M | 162.13% |
| May 31, 2021 | 7.20M | 506.32K | 7.57% |
| May 31, 2020 | Pro | Pro | Pro |
| May 31, 2019 | Pro | Pro | Pro |
| May 31, 2018 | Pro | Pro | Pro |
| May 31, 2017 | Pro | Pro | Pro |
| May 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lifeward | 24.50M |
| INVO Fertility | 6.94M |
| Beyond Air | 6.92M |
| Intelligent Bio Solutions | 3.58M |
| Tenon Medical | 3.23M |
| Sintx Technologies | 1.27M |
| iTonic Holdings | 305.22K |
| Nexalin Technology | 156.93K |
BMRA News
- 4 days ago - Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain - GlobeNewsWire
- 11 days ago - Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy - GlobeNewsWire
- 19 days ago - Vietnam Approves Biomerica's EZ Detect™ for Nationwide Distribution - GlobeNewsWire
- 7 weeks ago - Biomerica Reports Second Quarter Fiscal 2026 Financial Results - GlobeNewsWire
- 2 months ago - Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test - GlobeNewsWire
- 3 months ago - Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio - GlobeNewsWire
- 3 months ago - Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - GlobeNewsWire
- 4 months ago - Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand - GlobeNewsWire